Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma
Takuro Kameda,
Kotaro Shide,
Yuki Tahira,
Masaaki Sekine,
Seiichi Sato,
Junzo Ishizaki,
Masanori Takeuchi,
Keiichi Akizuki,
Ayako Kamiunten,
Haruko Shimoda,
Takanori Toyama,
Kouichi Maeda,
Kiyoshi Yamashita,
Noriaki Kawano,
Hiroshi Kawano,
Tomonori Hidaka,
Hideki Yamaguchi,
Yoko Kubuki,
Akira Kitanaka,
Hitoshi Matsuoka,
Kazuya Shimoda
Affiliations
Takuro Kameda
Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
Kotaro Shide
Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
Yuki Tahira
Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
Masaaki Sekine
Department of Internal Medicine, Koga General Hospital, Miyazaki 880-0041, Japan
Seiichi Sato
Department of Internal Medicine, Miyakonojo Medical Center, Miyakonojo 880-8510, Japan
Junzo Ishizaki
Department of Internal Medicine, Aisenkai Nichinan Hospital, Nichinan 887-0034, Japan
Masanori Takeuchi
Department of Internal Medicine, Aisenkai Nichinan Hospital, Nichinan 887-0034, Japan
Keiichi Akizuki
Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
Ayako Kamiunten
Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
Haruko Shimoda
Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
Takanori Toyama
Department of Internal Medicine, Miyazaki Prefectural Nobeoka Hospital, Nobeoka 882-0835, Japan
Kouichi Maeda
Department of Internal Medicine, Miyakonojo Medical Center, Miyakonojo 880-8510, Japan
Kiyoshi Yamashita
Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki 889-1692, Japan
Noriaki Kawano
Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki 889-1692, Japan
Hiroshi Kawano
Department of Internal Medicine, Koga General Hospital, Miyazaki 880-0041, Japan
Tomonori Hidaka
Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
Hideki Yamaguchi
Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
Yoko Kubuki
Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
Akira Kitanaka
Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan
Hitoshi Matsuoka
Department of Internal Medicine, Koga General Hospital, Miyazaki 880-0041, Japan
Kazuya Shimoda
Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
A retrospective chart survey of the clinical features of indolent adult T-cell leukemia/lymphoma (ATL) was conducted in the Miyazaki Prefecture, Japan. This study enrolled 24 smoldering-type ATLs, 10 favorable chronic-type ATLs, and 20 unfavorable chronic-type ATLs diagnosed between 2010 and 2018. Among them, 4, 3, and 10 progressed to acute-type ATLs during their clinical course. The median survival time (MST) in smoldering-type ATL and favorable chronic-type ATL was not reached, and their 4-year overall survival (OS) was 73% and 79%, respectively. Compared with this, the prognosis of unfavorable chronic-type ATL was poor. Its MST was 3.32 years, and the 4-year OS was 46% (p = 0.0095). In addition to the three features that determine the unfavorable characteristics of chronic-type ATL, namely, increased lactate dehydrogenase, increased blood urea nitrogen, and decreased albumin, the high-risk category by the indolent ATL-Prognostic Index, which was defined by an increment of soluble interleukin-2 receptor (sIL2-R) of >6000 U/mL, could explain the poor prognosis in indolent ATL patients. The level of sIL-2R might be an indicator of the initiation of therapy for indolent ATL.
